Lara Green
@laragreen.bsky.social
Research manager at Breakthrough T1D Canada (formerly JDRF), PhD in neurophys, mom of 2 little boys, jigsaw puzzle enthusiast, enjoyer of wine and food!
The workshop brought together regulators, payers, legal experts, researchers, industry experts, non-profit leaders and people with lived experience.
Let’s keep the conversation going. If you’re working in this space or have ideas - please connect!!
Let’s keep the conversation going. If you’re working in this space or have ideas - please connect!!
July 3, 2025 at 2:54 PM
The workshop brought together regulators, payers, legal experts, researchers, industry experts, non-profit leaders and people with lived experience.
Let’s keep the conversation going. If you’re working in this space or have ideas - please connect!!
Let’s keep the conversation going. If you’re working in this space or have ideas - please connect!!
Key themes that emerged:
✅ The value of cell therapies - both clinical outcomes AND what matters to people living with T1D
✅ The need for regulatory clarity for cell therapies
✅ Capitalizing on opportunities to collaborate
✅ How innovative models can enable reimbursement of cell therapies in Canada
✅ The value of cell therapies - both clinical outcomes AND what matters to people living with T1D
✅ The need for regulatory clarity for cell therapies
✅ Capitalizing on opportunities to collaborate
✅ How innovative models can enable reimbursement of cell therapies in Canada
July 3, 2025 at 2:54 PM
Key themes that emerged:
✅ The value of cell therapies - both clinical outcomes AND what matters to people living with T1D
✅ The need for regulatory clarity for cell therapies
✅ Capitalizing on opportunities to collaborate
✅ How innovative models can enable reimbursement of cell therapies in Canada
✅ The value of cell therapies - both clinical outcomes AND what matters to people living with T1D
✅ The need for regulatory clarity for cell therapies
✅ Capitalizing on opportunities to collaborate
✅ How innovative models can enable reimbursement of cell therapies in Canada
Fantastic! Thanks for going! And what an adorable science sidekick
June 15, 2025 at 12:07 PM
Fantastic! Thanks for going! And what an adorable science sidekick
The approval of Tzield makes screening even more important for Canadians. How will we find people who are early-stage #T1D that don’t yet have signs and symptoms but have an autoimmune attack silently killing beta cells.
Our approach is real-world evidence generation via www.canscreent1d.ca
Our approach is real-world evidence generation via www.canscreent1d.ca
Home - CanScreen T1D Research Consortium
The Canadian Population Screening for Risk of Type 1 Diabetes (CanScreen T1D) research consortium aims to launch a pilot screening program for children in Canada. The consortium studies the accessibility and feasibility of a T1D screening program through different research projects, ensuring equity, diversity, and inclusion measures in the program design.
www.canscreent1d.ca
May 6, 2025 at 8:34 PM
The approval of Tzield makes screening even more important for Canadians. How will we find people who are early-stage #T1D that don’t yet have signs and symptoms but have an autoimmune attack silently killing beta cells.
Our approach is real-world evidence generation via www.canscreent1d.ca
Our approach is real-world evidence generation via www.canscreent1d.ca
Such a ridiculous practice - same with NSERC. Always budget about 10% more than it will cost to hit closer to your target but not being ‘too high’. It’s a fine balance!
April 22, 2025 at 11:06 PM
Such a ridiculous practice - same with NSERC. Always budget about 10% more than it will cost to hit closer to your target but not being ‘too high’. It’s a fine balance!
When beta cells make insulin, C-peptide is ‘broken off’ and this can be measured in blood draws. C-peptide has been the ‘primary outcome’ for many #T1D preventative therapy trials, but it’s not a very sensitive test and can be costly.
April 15, 2025 at 6:00 PM
When beta cells make insulin, C-peptide is ‘broken off’ and this can be measured in blood draws. C-peptide has been the ‘primary outcome’ for many #T1D preventative therapy trials, but it’s not a very sensitive test and can be costly.
A biomarker is something measurable that indicates what’s happening in the body (an A1c is a biomarker of blood glucose).
With an increase in screening tests and preventative therapies, biomarkers of beta cell function are becoming more important.
With an increase in screening tests and preventative therapies, biomarkers of beta cell function are becoming more important.
April 15, 2025 at 6:00 PM
A biomarker is something measurable that indicates what’s happening in the body (an A1c is a biomarker of blood glucose).
With an increase in screening tests and preventative therapies, biomarkers of beta cell function are becoming more important.
With an increase in screening tests and preventative therapies, biomarkers of beta cell function are becoming more important.
For those curious why the same cells are effective on one trial (VX-880) and not another (VX-264)…
The 880 trial is putting the cells directly into the body and using immunosuppression drugs to protect them.
The 264 trial was putting the same cells in a ‘teabag’ device that goes under the skin
The 880 trial is putting the cells directly into the body and using immunosuppression drugs to protect them.
The 264 trial was putting the same cells in a ‘teabag’ device that goes under the skin
March 28, 2025 at 9:02 PM
For those curious why the same cells are effective on one trial (VX-880) and not another (VX-264)…
The 880 trial is putting the cells directly into the body and using immunosuppression drugs to protect them.
The 264 trial was putting the same cells in a ‘teabag’ device that goes under the skin
The 880 trial is putting the cells directly into the body and using immunosuppression drugs to protect them.
The 264 trial was putting the same cells in a ‘teabag’ device that goes under the skin